Development of a [89Zr]Zr-labeled Human Antibody using a Novel Phage-displayed Human scFv Library
©2024 American Association for Cancer Research..
PURPOSE: Tax-interacting protein 1 (TIP1) is a cancer-specific radiation-inducible cell surface antigen that plays a role in cancer progression and resistance to therapy. This study aimed to develop a novel anti-TIP1 human antibody for noninvasive PET imaging in patients with cancer.
EXPERIMENTAL DESIGN: A phage-displayed single-chain variable fragment (scFv) library was created from healthy donors' blood. High-affinity anti-TIP1 scFvs were selected from the library and engineered to human IgG1. Purified Abs were characterized by size exclusion chromatography high-performance liquid chromatography (SEC-HPLC), native mass spectrometry (native MS), ELISA, BIAcore, and flow cytometry. The labeling of positron emitter [89Zr]Zr to the lead Ab, L111, was optimized using deferoxamine (DFO) chelator. The stability of [89Zr]Zr-DFO-L111 was assessed in human serum. Small animal PET studies were performed in lung cancer tumor models (A549 and H460).
RESULTS: We obtained 95% pure L111 by SEC-HPLC. Native MS confirmed the intact mass and glycosylation pattern of L111. Conjugation of three molar equivalents of DFO led to the optimal DFO-to-L111 ratio of 1.05. Radiochemical purity of 99.9% and specific activity of 0.37 MBq/μg was obtained for [89Zr]Zr-DFO-L111. [89Zr]Zr-DFO-L111 was stable in human serum over 7 days. The immunoreactive fraction in cell surface binding studies was 96%. In PET, preinjection with 4 mg/kg cold L111 before [89Zr]Zr-DFO-L111 (7.4 MBq; 20 μg) significantly (P < 0.01) enhanced the tumor-to-muscle standard uptake values (SUVmax) ratios on day 5 compared with day 2 postinjection.
CONCLUSIONS: L111 Ab targets lung cancer cells in vitro and in vivo. [89Zr]Zr-DFO-L111 is a human antibody that will be evaluated in the first in-human study of safety and PET imaging.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:30 |
|---|---|
| Enthalten in: |
Clinical cancer research : an official journal of the American Association for Cancer Research - 30(2024), 7 vom: 01. Apr., Seite 1293-1306 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Singh, Abhay K [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
C6V6S92N3C |
|---|
| Anmerkungen: |
Date Completed 03.04.2024 Date Revised 03.04.2024 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1158/1078-0432.CCR-23-3647 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM367676508 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM367676508 | ||
| 003 | DE-627 | ||
| 005 | 20240403235318.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240127s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1158/1078-0432.CCR-23-3647 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1363.xml |
| 035 | |a (DE-627)NLM367676508 | ||
| 035 | |a (NLM)38277241 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Singh, Abhay K |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Development of a [89Zr]Zr-labeled Human Antibody using a Novel Phage-displayed Human scFv Library |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 03.04.2024 | ||
| 500 | |a Date Revised 03.04.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a ©2024 American Association for Cancer Research. | ||
| 520 | |a PURPOSE: Tax-interacting protein 1 (TIP1) is a cancer-specific radiation-inducible cell surface antigen that plays a role in cancer progression and resistance to therapy. This study aimed to develop a novel anti-TIP1 human antibody for noninvasive PET imaging in patients with cancer | ||
| 520 | |a EXPERIMENTAL DESIGN: A phage-displayed single-chain variable fragment (scFv) library was created from healthy donors' blood. High-affinity anti-TIP1 scFvs were selected from the library and engineered to human IgG1. Purified Abs were characterized by size exclusion chromatography high-performance liquid chromatography (SEC-HPLC), native mass spectrometry (native MS), ELISA, BIAcore, and flow cytometry. The labeling of positron emitter [89Zr]Zr to the lead Ab, L111, was optimized using deferoxamine (DFO) chelator. The stability of [89Zr]Zr-DFO-L111 was assessed in human serum. Small animal PET studies were performed in lung cancer tumor models (A549 and H460) | ||
| 520 | |a RESULTS: We obtained 95% pure L111 by SEC-HPLC. Native MS confirmed the intact mass and glycosylation pattern of L111. Conjugation of three molar equivalents of DFO led to the optimal DFO-to-L111 ratio of 1.05. Radiochemical purity of 99.9% and specific activity of 0.37 MBq/μg was obtained for [89Zr]Zr-DFO-L111. [89Zr]Zr-DFO-L111 was stable in human serum over 7 days. The immunoreactive fraction in cell surface binding studies was 96%. In PET, preinjection with 4 mg/kg cold L111 before [89Zr]Zr-DFO-L111 (7.4 MBq; 20 μg) significantly (P < 0.01) enhanced the tumor-to-muscle standard uptake values (SUVmax) ratios on day 5 compared with day 2 postinjection | ||
| 520 | |a CONCLUSIONS: L111 Ab targets lung cancer cells in vitro and in vivo. [89Zr]Zr-DFO-L111 is a human antibody that will be evaluated in the first in-human study of safety and PET imaging | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Zirconium-89 |2 NLM | |
| 650 | 7 | |a NTM296JU95 |2 NLM | |
| 650 | 7 | |a Radioisotopes |2 NLM | |
| 650 | 7 | |a Single-Chain Antibodies |2 NLM | |
| 650 | 7 | |a Zirconium |2 NLM | |
| 650 | 7 | |a C6V6S92N3C |2 NLM | |
| 650 | 7 | |a Deferoxamine |2 NLM | |
| 650 | 7 | |a J06Y7MXW4D |2 NLM | |
| 700 | 1 | |a Lewis, Calvin D |e verfasserin |4 aut | |
| 700 | 1 | |a Boas, Cristian A W V |e verfasserin |4 aut | |
| 700 | 1 | |a Diebolder, Philipp |e verfasserin |4 aut | |
| 700 | 1 | |a Jethva, Prashant N |e verfasserin |4 aut | |
| 700 | 1 | |a Rhee, Aaron |e verfasserin |4 aut | |
| 700 | 1 | |a Song, Jong Hee |e verfasserin |4 aut | |
| 700 | 1 | |a Goo, Young Ah |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Shunqian |e verfasserin |4 aut | |
| 700 | 1 | |a Nickels, Michael L |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Yongjian |e verfasserin |4 aut | |
| 700 | 1 | |a Rogers, Buck E |e verfasserin |4 aut | |
| 700 | 1 | |a Kapoor, Vaishali |e verfasserin |4 aut | |
| 700 | 1 | |a Hallahan, Dennis E |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical cancer research : an official journal of the American Association for Cancer Research |d 1995 |g 30(2024), 7 vom: 01. Apr., Seite 1293-1306 |w (DE-627)NLM09444479X |x 1557-3265 |7 nnns |
| 773 | 1 | 8 | |g volume:30 |g year:2024 |g number:7 |g day:01 |g month:04 |g pages:1293-1306 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1158/1078-0432.CCR-23-3647 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 30 |j 2024 |e 7 |b 01 |c 04 |h 1293-1306 | ||